Effect of fluvastatin and pravastatin, HMG-coA reductase inhibitors, on fluconazole activity against Candida albicans

James D. Nash, David S. Burgess, Robert L. Talbert

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Synergy between fluvastatin, at clinically unachievable concentrations, and fluconazole against Candida albicans has been reported. The purpose of the present study was to evaluate the in-vitro activity of fluconazole alone and in combination with clinically achievable concentrations of pravastatin and fluvastatin against C. albicans. In-vitro susceptibility and synergy testing were performed against clinical isolates of C. albicans with fluconazole, pravastatin and fluvastatin. Both checkerboard method and time-kill studies were performed. MICs for fluconazole ranged from 0.5 (susceptible) to >256 mg/L (resistant) at 24 h. All isolates had MICs >2 mg/L for both statins. No synergy or antagonism was observed with fluconazole in combination with either agent against any isolate of C. albicans by the checkerboard assay or time-kill studies. Clinically achievable concentrations of pravastatin and fluvastatin did not affect the in-vitro activity of fluconazole against C. albicans.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalJournal of Medical Microbiology
Volume51
Issue number2
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Effect of fluvastatin and pravastatin, HMG-coA reductase inhibitors, on fluconazole activity against Candida albicans'. Together they form a unique fingerprint.

Cite this